Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Collegium Pharmaceutical from “Buy” to “Hold,” while other analysts delivered mixed views. The stock retains a “Moderate Buy” consensus rating with an average price target of $52.60.
• Collegium exceeded second-quarter expectations, reporting EPS of $1.92 versus $1.72 expected and revenue of approximately $199.9 million, up 6.3% year over year. Growth was supported by its ADHD portfolio, including a 41% increase in JORNAY PM revenue.
• The company lowered full-year product-revenue and adjusted-EBITDA guidance, citing weaker pricing and Nucynta performance. Its pain portfolio declined 9% year over year, and GAAP results swung to a $15.1 million net loss.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) was downgraded by analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

Several other research firms also recently weighed in on COLL. Zacks Research downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Needham & Company LLC dropped their target price on Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating on the stock in a report on Thursday. Weiss Ratings reissued a "hold (c)" rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Truist Financial upgraded Collegium Pharmaceutical to a "strong-buy" rating in a report on Monday, June 15th. Finally, Piper Sandler reaffirmed a "neutral" rating and issued a $43.00 price target (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $52.60.

Collegium Pharmaceutical Stock Up 1.2%

Shares of NASDAQ COLL opened at $29.47 on Friday. The company has a current ratio of 1.14, a quick ratio of 1.62 and a debt-to-equity ratio of 3.50. Collegium Pharmaceutical has a 12 month low of $28.01 and a 12 month high of $50.79. The firm has a market capitalization of $955.71 million, a PE ratio of 23.77 and a beta of 0.73. The firm has a fifty day simple moving average of $34.78 and a two-hundred day simple moving average of $37.07.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The business had revenue of $199.88 million for the quarter, compared to analysts' expectations of $199.62 million. During the same period in the previous year, the firm posted $1.68 EPS. The business's revenue was up 6.3% on a year-over-year basis. Equities analysts expect that Collegium Pharmaceutical will post 6.76 earnings per share for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $196,972,000. Deutsche Bank AG purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $1,270,000. Bank of New York Mellon Corp bought a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $8,506,000. State of Wyoming bought a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $218,000. Finally, One Wealth Advisors LLC bought a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $310,000.

Key Stories Impacting Collegium Pharmaceutical

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
• Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
• Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
• Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source